FDA-approved hemophilia drug to be made in Denmark
Danish-American company CMC Biologics has struck a deal with a US-based pharmaceutical group to manufacture its FDA approved hemophilia medicine at a site in Denmark.
BY LONNI LYNGE
CMC Biologics, which boasts facilities in both the US and Europe, has signed an agreement with US-based drug company CSL Behring to help with the manufacturing of the group’s Afstyla, a long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A. This is according to a press release from the two partners.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish company joins Ebola battle
For abonnenter
Novo to invest DKK 2 billion and create 450 jobs
For abonnenter
